Ciara Kennedy, Sorriso Pharmaceuticals CEO
February 27, 2025 05:10 AM ESTUpdated 06:15 AM
R&D

Start­up work­ing on oral an­ti­bod­ies shares ear­ly ul­cer­a­tive col­i­tis da­ta

Max Gelman

Senior Editor

Pri­vate start­up Sor­riso Phar­ma­ceu­ti­cals laid out Phase 1b da­ta at a med­ical con­fer­ence last week­end as part of its ef­fort to bring an oral an­ti­body …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

FDA's Pe­ter Marks re­signs, say­ing he won't ac­cept Kennedy's 'mis­in­for­ma­tion and lies'

Blue­bird gets new M&A bid, seek­ing to top pri­vate eq­ui­ty of­fer

BioN­Tech de­tails promis­ing mid-stage da­ta for its PD-L1xVEGF in ag­gres­sive lung can­cer

No­vo inks sec­ond obe­si­ty deal of the week, with Lex­i­con oral drug part­ner­ship worth up to $1B

Eu­ro­pean reg­u­la­tor re­jects Lil­ly's Alzheimer’s drug over po­ten­tial­ly fa­tal side ef­fects

‘Peo­ple will die’: End of NIH grants guts work be­tween aca­d­e­mics and com­pa­nies to counter next pan­dem­ic

A service from the Financial Times